No photo of Manu Jain

View Scopus Profile

Manu Jain

  • 2718 Citations
1992 …2021
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

My primary research interest is in lung repair after acute injury with a focus on TGF-beta mediated signaling. We have identified mitochondrial generated reactive oxygen species as important in TGF-bête mediated gene expression and are working to identify novel therapeutic targets in this pathway. We are also interested in modulating the ubiquitin-proteosomal pathway as a therapeutic target for tissue fibrosis. I have a clinical translational interest in Cystic Fibrosis. I am the site co-PI for the CF Foundation sponsored clinical trial network, The Therapeutic Development Network. I am also interested in the CF outcomes, especially related to chronic infection with Pseudomonas aeruginosa.

Certifications and Licenses

Pulmonary Disease
Internal Medicine
Critical Care Medicine

Training Experience

1990Internship, University of Chicago Pritzker School of Medicine
1992Residency, Univ. of Chicago Hospital
1996Fellowship, University of Chicago

Education/Academic qualification

MD, University of Chicago

… → 1989

Keywords

  • Critical Care
  • Cystic Fibrosis
  • Fibrosis
  • Lungs / Breathing Problems
  • TGF-beta

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 23 Similar Profiles
Cystic Fibrosis Medicine & Life Sciences
Lung Medicine & Life Sciences
Adult Respiratory Distress Syndrome Medicine & Life Sciences
Acute Lung Injury Medicine & Life Sciences
Fibrosis Medicine & Life Sciences
Pulmonary Fibrosis Medicine & Life Sciences
Pseudomonas aeruginosa Medicine & Life Sciences
Systemic Scleroderma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2002 2021

Prot #MRT5005-101: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 (CO-hCFTR mRNA/ICE LNP) Administered by Nebulization to

Jain, M.

Rho, Inc., Translate Bio, Inc.

12/7/18 → 12/7/21

Project: Research project

Prot #PTI-428-06: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects with Cystic Fibrosis

Jain, M.

MS Clinical Services, LLC, Proteostasis Therapeutics, Inc.

10/29/18 → 10/29/21

Project: Research project

Prot #JBT101-CF-002: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Jain, M.

Corbus Pharmaceuticals, Inc.

10/16/18 → 10/16/19

Project: Research project

Prot #PTI-808-01: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis

Jain, M.

Chiltern International, Inc., Proteostasis Therapeutics, Inc.

8/2/18 → 8/2/21

Project: Research project

Prot #VX17-445-105: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Jain, M.

Greenphire, Inc., Vertex Pharmaceuticals Incorporated

7/29/18 → 7/29/21

Project: Research project

Research Output 1992 2018

Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD

Jain, M., Budinger, GRS., Jovanovic, B., Dematte, J., Duffey, S. & Mehta, J., Sep 1 2018, In : Bone Marrow Transplantation. 53, 9, p. 1124-1130 7 p.

Research output: Contribution to journal › Article

Graft vs Host Disease
Lung
Safety
Multiple Myeloma
Bortezomib

Inflammatory pathways are upregulated in the nasal epithelium in patients with idiopathic pulmonary fibrosis

Sala, M. A., Balderas-Martínez, Y. I., Buendía-Roldan, I., Abdala-Valencia, H., Nam, K., Jain, M., Bhorade, S. M., Bharat, A., Reyfman, P. A., Ridge, K. M., Pardo, A., Sznajder, J. I., Budinger, GR. S., Misharin, A. & Selman, M., Nov 26 2018, In : Respiratory Research. 19, 1, 233.

Research output: Contribution to journal › Article

Idiopathic Pulmonary Fibrosis
Nasal Mucosa
Nose
Up-Regulation
RNA Sequence Analysis
1 Citations

Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement

Heltshe, S. L., Rowe, S. M., Skalland, M., Baines, A. & Jain, M., Jun 1 2018, In : American Journal of Respiratory and Critical Care Medicine. 197, 11, p. 1483-1486 4 p.

Research output: Contribution to journal › Letter

Cystic Fibrosis
ivacaftor
4 Citations

Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR

VX14-809-106 Investigator Group, Mar 1 2018, In : Journal of Cystic Fibrosis. 17, 2, p. 228-235 8 p.

Research output: Contribution to journal › Article

Cystic Fibrosis
Lung Diseases
Forced Expiratory Volume
Safety
ivacaftor drug combination lumacaftor

Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis

Soberanes, S., Misharin, A. V., Jairaman, A., Morales-Nebreda, L., McQuattie-Pimentel, A. C., Cho, T., Hamanaka, R. B., Meliton, A. Y., Reyfman, P. A., Walter, J. M., Chen, C-I., Chi, M., Chiu, S., Gonzalez-Gonzalez, F. J., Antalek, M., Abdala-Valencia, H., Chiarella, S. E., Sun, K. A., Woods, P. S., Ghio, A. J. & 12 othersJain, M., Perlman, H., Ridge, K. M., Morimoto, R. I., Sznajder, J. I., Balch, W. E., Bhorade, S. M., Bharat, A., Prakriya, M., Chandel, N. S., Mutlu, G. M. & Budinger, G. R. S., Oct 11 2018, In : Cell Metabolism.

Research output: Contribution to journal › Article

Metformin
Air Pollution
Electron Transport
Particulate Matter
Alveolar Macrophages